Literature DB >> 17535994

The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma.

Riccardo Giannini1, Clara Ugolini, Cristiana Lupi, Agnese Proietti, Rossella Elisei, Giuliana Salvatore, Piero Berti, Gabriele Materazzi, Paolo Miccoli, Massimo Santoro, Fulvio Basolo.   

Abstract

CONTEXT: Papillary thyroid carcinoma (PTC) is frequently multifocal. Independent PTC foci may occur either from intraglandular metastases from a single dominant tumor or as unrelated neoplastic clones. In rare cases, the simultaneous presence of PTC foci of different histopathological subtypes points to independent sites of tumor formation.
OBJECTIVES: We examined the pattern of BRAF mutations in noncontiguous tumor foci and node metastases from 69 patients affected by multicentric PTC. These included 19 cases characterized by the simultaneous presence of different PTC histopathological variants.
DESIGN: BRAF (exon 15) mutation was examined by PCR-single strand conformational polymorphism followed by DNA sequencing in laser-capture microdissected tissue samples.
RESULTS: Discordant patterns of BRAF mutation were found in about 40% of the multifocal PTCs. In node metastases, BRAF mutations were, in most but not all the cases, concordant with the dominant tumor. A discordant pattern of BRAF mutation was also found in about 50% of the cases in which multiple foci of different histopathological variants were present.
CONCLUSIONS: The heterogeneous distribution of BRAF mutations suggests that discrete tumor foci in multifocal PTC may occur as independent tumors. This information has to be considered in the design of targeted therapeutic approaches with BRAF pathway inhibitors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17535994     DOI: 10.1210/jc.2007-0594

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  29 in total

1.  Amplification of thymosin beta 10 and AKAP13 genes in metastatic and aggressive papillary thyroid carcinomas.

Authors:  Liliána Z Fehér; Gábor Pocsay; László Krenács; Agnes Zvara; Enikő Bagdi; Réka Pocsay; Géza Lukács; Ferenc Győry; Andrea Gazdag; Erzsébet Tarkó; László G Puskás
Journal:  Pathol Oncol Res       Date:  2011-12-11       Impact factor: 3.201

2.  Predictors of incomplete response to therapy among Filipino patients with papillary thyroid cancer in a tertiary hospital.

Authors:  E S Mendoza; A A Lopez; V A U Valdez; E C Cunanan; B J Matawaran; S A Kho; M H Sero-Gomez
Journal:  J Endocrinol Invest       Date:  2015-06-03       Impact factor: 4.256

3.  Applying new clinicopathological characteristics to prognostication in advanced thyroid carcinoma.

Authors:  Maria E Cabanillas; Steven I Sherman
Journal:  Endocr Relat Cancer       Date:  2012-04-10       Impact factor: 5.678

4.  VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations.

Authors:  Jong-In Na; Jo-Heon Kim; Hye-Jeong Kim; Hee-Kyung Kim; Kyung-Sub Moon; Ji-Shin Lee; Jae-Hyuk Lee; Kyung-Hwa Lee; Jong-Tae Park
Journal:  Virchows Arch       Date:  2015-04-19       Impact factor: 4.064

5.  BRAFV600E Mutation: Has It a Role in Cervical Lymph Node Metastasis of Papillary Thyroid Cancer?

Authors:  Neslihan Kurtulmus; Burak Ertas; Yesim Saglican; Hakan Kaya; Umit Ince; Mete Duren
Journal:  Eur Thyroid J       Date:  2016-08-20

6.  A Case of Multifocal Papillary Thyroid Carcinoma Consisting of One Encapsulated Follicular Variant with BRAF K601E Mutation and Three Conventional Types with BRAF V600E Mutation.

Authors:  Wook Youn Kim; Young Sin Ko; Tae Sook Hwang; Hye Seung Han; So Dug Lim; Wan Seop Kim; Seo Young Oh
Journal:  Korean J Pathol       Date:  2013-06-25

Review 7.  The paramount role of cytokines and chemokines in papillary thyroid cancer: a review and experimental results.

Authors:  Poupak Fallahi; Silvia Martina Ferrari; Simona Piaggi; Michaela Luconi; Giulia Cantini; Stefania Gelmini; Giusy Elia; Ilaria Ruffilli; Alessandro Antonelli
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

Review 8.  Occult thyroid carcinoma.

Authors:  J Boucek; J Kastner; J Skrivan; E Grosso; B Gibelli; G Giugliano; J Betka
Journal:  Acta Otorhinolaryngol Ital       Date:  2009-12       Impact factor: 2.124

9.  Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.

Authors:  Julio C Ricarte-Filho; Mabel Ryder; Dhananjay A Chitale; Michael Rivera; Adriana Heguy; Marc Ladanyi; Manickam Janakiraman; David Solit; Jeffrey A Knauf; R Michael Tuttle; Ronald A Ghossein; James A Fagin
Journal:  Cancer Res       Date:  2009-06-01       Impact factor: 12.701

10.  Geographical mapping of a multifocal thyroid tumour using genetic alteration analysis & miRNA profiling.

Authors:  Sinéad T Aherne; Paul C Smyth; Richard J Flavin; Susan M Russell; Karen M Denning; Jing Huan Li; Simone M Guenther; John J O'Leary; Orla M Sheils
Journal:  Mol Cancer       Date:  2008-12-04       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.